Bladder cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• HER2 47
• PD-1 19
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• ERK 0
• MYC 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 42+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Updated 22 Sept 2026

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Jazz Pharmaceuticals· Source

• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Daiichi Sankyo· Source

• DESTINY-PANTUMOUR04

  NCT07124000· AstraZeneca· Source

• TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

  NCT07038928· AstraZeneca· Source

• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

  NCT05911295· Seagen, a wholly owned subsidiary of Pfizer· Source

• A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· Seagen, a wholly owned subsidiary of Pfizer· Source

• ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

  NCT06973161· AstraZeneca· Source

• Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.

  NCT07379268· Qilu Hospital of Shandong University· Source

• DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

  NCT05786716· Cancer Research UK· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 22
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 78
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 93
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 76
• Genome-Wide Association Study 18

• Early Detection of Bladder Cancer Using Advanced Feature Engineering and Swarm Intelligence Optimization on EHRs.

  IEEE Trans Biomed Eng, Nov 2026

• Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

  Expert Opin Biol Ther, Sept 2026

• Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic review.

  BJU Int, Aug 2026

• Pan-cancer multi-omics machine learning defines a lactylation-associated immune-excluded tumor state with proteomic and experimental corroboration.

  Comput Biol Chem, Jul 2026

• Non-invasive diagnostic evaluation of urinary exosomal let-7c cluster expression in bladder cancer using machine learning approaches.

  BMC Cancer, Jul 2026

• Development of multiphasic CT-based delta-radiomics model for predicting postoperative recurrence risk in bladder cancer.

  BMC Med Imaging, Jul 2026

• Interpretable machine learning model of contrast-enhanced CT radiomics for predicting post-BCG recurrence in high-grade non-muscle-invasive bladder cancer.

  World J Urol, Jul 2026

• Machine learning-based identification of basement membrane-related signature to predict recurrence and immunotherapy benefit in bladder cancer.

  Immunol Res, Jun 2026

• Application Value of Radiomics-Based Machine Learning for Preoperative Risk Stratification of Bladder Cancer: Systematic Review and Meta-Analysis.

  J Med Internet Res, Jun 2026

• Machine-learning-assisted artificial olfactory colorimetric sensor array for bladder cancer early detection from urinary volatile organic compounds.

  Biosens Bioelectron, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.